These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28335760)

  • 1. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
    Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
    Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.
    Weber DG; Casjens S; Johnen G; Bryk O; Raiko I; Pesch B; Kollmeier J; Bauer TT; Brüning T
    PLoS One; 2014; 9(12):e114483. PubMed ID: 25469901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
    Hollevoet K; Reitsma JB; Creaney J; Grigoriu BD; Robinson BW; Scherpereel A; Cristaudo A; Pass HI; Nackaerts K; Rodríguez Portal JA; Schneider J; Muley T; Di Serio F; Baas P; Tomasetti M; Rai AJ; van Meerbeeck JP
    J Clin Oncol; 2012 May; 30(13):1541-9. PubMed ID: 22412141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
    Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
    Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
    Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
    Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
    Creaney J; Sneddon S; Dick IM; Dare H; Boudville N; Musk AW; Skates SJ; Robinson BW
    Dis Markers; 2013; 35(2):119-27. PubMed ID: 24167356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
    Tsim S; Kelly C; Alexander L; McCormick C; Thomson F; Woodward R; Foster JE; Stobo DB; Paul J; Maskell NA; Chalmers A; Blyth KG
    BMJ Open; 2016 Nov; 6(11):e013324. PubMed ID: 27884852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
    Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.